Related Experiment Video
Updated: Aug 9, 2026
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
Immunoreactive fucosylceramide as a B-cell differentiation marker
H Nakamura1, H Yamada, H Kitagawa
1Department of Pathology, Saitama Medical Center, Saitama Medical School, Kawagoe, Japan.
Insights
The monoclonal antibody PC47H targets fucosylceramide (FC), a marker found on mature B cells and certain B-cell malignancies. This antibody can distinguish B-cell subsets and aid in diagnosing lymphoid cancers.
Area of Science:
- Immunology
- Cell Biology
- Oncology
Background:
- Fucosylceramide (FC) is a glycosphingolipid found on cell surfaces.
- Understanding the expression patterns of FC is crucial for identifying specific cell types and disease states.
Purpose of the Study:
- To investigate the reactivity of the monoclonal antibody PC47H against fucosylceramide (FC) on lymphoid cells.
- To determine if PC47H can serve as a marker for B-cell differentiation and lymphoid malignancies.
Main Methods:
- Flow cytometry was used to assess the reactivity of mAb PC47H with various lymphoid cell populations.
- Immunoelectron microscopy was employed to localize FC within cells.
Main Results:
- mAb PC47H specifically recognized FC on pokeweed mitogen (PWM)-stimulated B blasts, plasma cells, and germinal center cells.
- FC was highly expressed on B-cell lymphoma, multiple lymphoma, and myeloma cell lines, indicating higher expression in mature B cells.
- FC was localized to the plasma membrane and rough endoplasmic reticulum.
Conclusions:
- mAb PC47H is a unique marker for B-cell differentiation, useful for studying B-cell activation and maturation.
- PC47H can be utilized for clonal analysis of lymphoid malignancies, aiding in diagnosis and research.
Abstract:
The reactivity of PC47H, a monoclonal antibody (mAb) directed against fucosylceramide, with cells of lymphoid lineage was examined. Immunoreactive fucosylceramide (FC) was recognized only in pokeweed mitogen (PWM)-stimulated B blasts, plasma cells and germinal center cells. mAb PC47H did not react with T cells at different stages or with peripheral blood B cells. Furthermore, FC was expressed abundantly in blastic cells of B-cell lymphoma, multiple lymphoma and myeloma cell lines KMS-12-BM and KMS-12-PE. In other words, FC was expressed more strongly in mature than in immature B cells. Immunoelectron microscopy showed that FC was located in the plasma membrane and rough endoplasmic reticulum. mAb PC47H can therefore be used as a unique B-cell differentiation marker for study of B-cell activation and differentiation and clonal analysis of lymphoid malignancies.
